Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 756

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 756
---
 additional paid-incapital equals to zero. F-22

As of December 31, 2024 and 2023, the ordinary shares reflected in the consolidated balance sheets are reconciled in the following table:

|                                                                                                                   |     | Shares |            |   |     | Amount |             |   |
| Ordinary shares subject to possible redemption – December 31, 2022                                                |     |        |  8,250,000 |   |     |        |  85,371,600 |   |
| Redemption of shares ($10.92per share)                                                                            |     |        | (3,712,171 | ) |     |        | (40,536,908 | ) |
| Subsequent measurement of Class A ordinary shares subject to possible redemption (income earned on Trust Account) |     |        |          — |   |     |        |   3,843,271 |   |
| Subsequent measurement of Class A ordinary shares subject to possible redemption (extension deposit)              |     |        |          — |   |     |        |   1,800,000 |   |
| Ordinary shares subject to possible redemption – December 31, 2023                                                |     |        |  4,537,829 |   |     | $      |  50,477,963 |   |
| Redemption of shares ($11.47per share)                                                                            |     |        | (3,785,992 | ) |     |        | (43,425,328 | ) |
| Subsequent measurement of Class A ordinary shares subject to possible redemption (income earned on Trust Account) |     |        |          — |   |     |        |   1,578,042 |   |
| Subsequent measurement of Class A ordinary shares subject to possible redemption (extension deposit)              |     |        |          — |   |     |        |     390,328 |   |
| Ordinary shares subject to possible redemption – December 31, 2024                                                |     |        |    751,837 |   |     |        |   9,021,005 |   |

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $ 250,000 . The Company has not experienced losses on this account.

Net Income Per Ordinary Share

The Company